ライフサイエンスコーパス: copeptin

1 eased, as assessed by the cosecreted protein copeptin.

2 veral novel biomarkers - galectin-3, ST2 and copeptin.

3 receiver operating characteristic curves for copeptin (0.75) and NTproBNP (0.76) were similar.

4 eath or HF at 1 year (adjusted hazard ratio: copeptin, 1.71; MR-proADM, 1.96; MR-proANP, 2.20; all p

5 entified an increased risk of CV death or HF(copeptin: 13.2% vs. 5.0%, p < 0.001; MR-proADM: 15.8% vs

6 higher in samples with raised osmolality or copeptin (a surrogate marker for AVP).

7 ove the median of approximately 900 pmol/L), copeptin above the median (approximately 7 pmol/L) was a

8 We analyzed the association of copeptin, an established surrogate for AVP, with paramet

9 prospectively study the association between copeptin and 1-year mortality in patients with out-of-ho

10 We compared the prognostic value of copeptin and an established marker, N-terminal pro-B-typ

11 A negative copeptin and cTnI at baseline ruled out AMI for 58% of p

12 Both abnormal copeptin and cTnI were predictors of death at 180 days (

13 ion showed significant differences in SMD of copeptin, and the heterogeneity among studies was signif

14 For both admission and day 3 copeptin, association with 1-year mortality existed for

15 With use of copeptin concentration as a surrogate measure of AVP con

16 ng fractional uric acid excretion and plasma copeptin concentration, may further improve the diagnost

17 A close correlation between copeptin concentrations and serum osmolality existed in

18 Furthermore, saline-induced changes in copeptin concentrations correlated with changes in AVP c

19 lasma arginine vasopressin (AVP), and plasma copeptin concentrations from 50 patients with hyponatrem

20 osmotic thresholds (type B); 44% had normal copeptin concentrations independent of osmolality (type

21 osmolality (type C), and 12% had suppressed copeptin concentrations independent of osmolality (type

22 Ten percent of patients had grossly elevated copeptin concentrations independent of serum osmolality

23 endent of serum osmolality (type A); 14% had copeptin concentrations that increased linearly with ris

24 ts was characterized by a linear decrease in copeptin concentrations with increasing serum osmolality

25 ocin precursor and suggests that the loss of copeptin contributes to 87STOP pathogenicity.

26 is suggests that early measurement of plasma copeptin could provide better prognostic information abo

27 undetected by cTnI at 0 h were detected with copeptin >14 pmol/l in 10 (53%) of 19 patients.

28 y the initial cTnI alone were picked up with copeptin >14 pmol/l in 23 (72%) of 32 patients.

29 corresponding wild-type proteins from which copeptin had been deleted, leading to the following conc

30 h or heart failure with both biomarkers (log copeptin [hazard ratio, 2.33], log NTproBNP [hazard rati

31 s provides an explanation for the absence of copeptin in the more stable oxytocin precursor and sugge

32 sistent argument for a role for glycosylated copeptin in vasopressin precursor folding in vivo, copep

33 -terminal pro-endothelin-1 (CT-proET-1), and copeptin, in 3717 patients with stable coronary artery d

34 Copeptin is a stable arginine vasopressin precursor asso

35 Copeptin is secreted from the pituitary early in the cou

36 A positive association was found between the copeptin level and the presence of renal cysts (odds rat

37 assess the prognostic significance of plasma copeptin level on functional outcome and mortality in pa

38 In multivariable analyses, the copeptin level was associated inversely with eGFR (beta=

39 An elevated plasma copeptin level was associated with an increased risk of

40 e goal of this study was to demonstrate that copeptin levels <14 pmol/L allow ruling out acute myocar

41 Copeptin levels and a contemporary sensitive cTnI (99 th

42 acroalbuminuria, and perhaps, elevated serum copeptin levels in affected adults.

43 The 529 women and 481 men had median copeptin levels of 3.0 and 5.2 pmol/L, respectively (P<0

44 rdized mean difference (SMD) was that plasma copeptin levels were found to be significantly higher in

45 Copeptin levels were log-transformed.

46 Copeptin may predict adverse outcome, especially in thos

47 In the 980 patients, copeptin (measured at days 3 to 5) was elevated in patie

48 ic performance of C-terminal provasopressin (copeptin), midregional pro-adrenomedullin (MR-proADM), a

49 in in vasopressin precursor folding in vivo, copeptin most probably assisting refolding by facilitati

50 Copeptin, MR-proADM, and MR-proANP are complementary pro

51 Copeptin, MR-proADM, and MR-proANP are emerging biomarke

52 We measured copeptin, MR-proADM, and MR-proANP concentrations in 4,4

53 Novel biomarkers (Copeptin, MR-proADM, and MR-proANP) and common signs and

54 With logistic regression analysis, copeptin (odds ratio, 4.14, P<0.0005) and NTproBNP (odds

55 curve (0.84) than for NTproBNP (P<0.013) or copeptin (P<0.003) alone, respectively.

56 SCD) was estimated by plasma renin (PRC) and copeptin (PCC) concentrations.

57 copeptin were mutually adjusted, only day 3 copeptin remained associated with 1-year mortality in a

58 ed by 2 independent cardiologists blinded to copeptin results.

59 utation deletes the precursor's glycosylated copeptin segment, which has been considered unnecessary

60 higher in samples with raised osmolality and copeptin (surrogate marker for AVP).

61 Copeptin, the C-terminal part of provasopressin, has eme

62 Copeptin, the C-terminal part of the vasopressin prohorm

63 Day 3 copeptin was superior to admission copeptin: this could permit identification of out-of-hos

64 Adding copeptin to cTnI allowed safe rule out of AMI with a neg

65 Copeptin was assessed at admission and day 3.

66 Day 3 copeptin was associated with 1-year mortality in a dose-

67 fter multivariate analysis, higher admission copeptin was associated with 1-year mortality with a thr

68 Plasma copeptin was highest on admission (n=132, P<0.001, day 1

69 Day 3 copeptin was superior to admission copeptin: this could

70 High levels of copeptin were associated with 1-year mortality independe

71 When admission and day 3 copeptin were mutually adjusted, only day 3 copeptin rem

72 However, the positive association of copeptin with poor prognosis after stroke was consistent

73 ssion analysis to explore the association of copeptin with renal function parameters as well as kidne